Cyemptive Technologies Announces Liaison Partnership with Netherlands-based Partnership for Cyber Security Innovation
9.7.2024 08:00:00 EEST | Business Wire | Press release
Cyemptive Technologies, an award-winning provider of pre-emptive cybersecurity solutions for business and government, today announced that it has entered into a liaison partnership with Partnership for Cyber Security Innovation (PCSI) in the Netherlands.
PCSI is a public/private sector network of government bodies, research institutes, corporations and startups/scaleups and designed to make Dutch society more secure and resilient against future cyber-attacks. Its major partners include leading public and private sector organizations such as ABN Amro, Achmea, ASML, ING, Dutch Tax & Customs Administration and TNO.
“I am excited that Cyemptive joins the PCSI ecosystem as a Liaison Partner,” said Reinder Wolthuis, Program Manager PCSI. “PCSI is about innovation and collaboration. As a relatively young and innovative cybersecurity company and Cyemptive’s mission to transform the cybersecurity industry to a fully proactive approach, Cyemptive is a natural fit for PCSI.”
PCSI is an open innovation platform that aims to make Dutch society more secure and resilient against future cyber-attacks. By giving them a platform for sharing knowledge and expertise, PCSI offers its core partners a unique opportunity to develop innovative cybersecurity solutions that boost the cyber resilience of both individual companies and Dutch society in general. The innovation projects include a variety of cybersecurity challenges, from advanced detection systems to software for structuring data automatically and human-factor solutions.
“Being part of PCSI provides organizations with a platform to influence cybersecurity policies and standards,” said Rob Pike, founder and CEO of Cyemptive. “This ensures that their specific needs and concerns are considered in the development of industry regulations and guidelines.”
Cyemptive offers military-grade layers of pre-emptive cybersecurity protection that are essential add-ons for businesses to achieve cyber safety. Cyemptive’s ZeroStrike allows customers to be in command of their security by eliminating damage even from unknown attack vectors pre-zero day discovery. With Cyemptive ZeroStrike there is no need for recovery and remediation, an industry first capability.
About PCSI
Partnership for Cyber Security Innovation makes a vital contribution to a secure and resilient digital society through innovation in cybersecurity. Within PCSI, applicable, innovative cybersecurity solutions are developed that allow stakeholders in Dutch society to protect themselves against the cyber-attacks of tomorrow. By working together closely via an innovative ecosystem, PCSI partners connect applied research, current data and issues from society in the field of cybersecurity in a unique way.
About Cyemptive Technologies
Headquartered in Seattle, Wash., Cyemptive has been on a mission to make large organizations cyber safe since 2014. Today, Cyemptive’s award-winning software, services and support are used by businesses and government entities worldwide. It is the winner of the Department of Homeland Security’s Border Security Technology Consortium (BSTC) competition for most innovative border security-related solution in the market, as well as 11 ‘ASTORS’ Homeland Security Awards from American Security Today in 2023 and received 10 awards in 2022 – more than any other company. Cyemptive’s leadership team is comprised of executives from several of the world’s most powerful technology and security organizations, including the former CIO of Microsoft and the former Chief Computer Architect for the National Security Agency. More information about Cyemptive Technologies is available at www.cyemptive.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240707748050/en/
Contacts
Belinda Young
BYPR
+1 206-932-3145
byoung@bypr.com
Rob Pike
Cyemptive Technologies
+1 425-341-9800
info@cyemptive.com
Wessel Graatsma
Vice President Cybersecurity Solutions Europe
+31 6 4868 2748
wgraatsma@cyemptive.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom